Jupiter Neurosciences, Inc. · NASDAQ:JUNS
Jupiter Neurosciences — Investor Presentation (April 2026)
14 slides from Jupiter Neurosciences's investor presentation, Apr 2, 2026
Slide 1: Jupiter Neurosciences, Inc. (NASDAQ: JUNS)
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) March 2026
Slide 2: Cautionary Note on Forward Looking Statements
CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS This Presentation contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about
Slide 3: Highlights
Highlights Founded 2016 with a goal of making resveratrol more bioavailable Breakthrough Therapeutics Platform — JOTROL™: 2021 Phase 1 study proved success w. 9X bioavailability. Patent protected through 2036 Clinical Pipeline: Parkinson’s Phase IIa trial is in process. Post PD results, we expect to
Slide 4: JOTROL vs Resveratrol
JOTROL™ vs Resveratrol NASDAQ: JUNS
Slide 5: JOTROL - Broad Applicability Across Disease Areas
JOTROL™ - Broad Applicability Across Disease Areas Alzheimer's Disease Parkinson's Disease Target: Neuroinflammation and Target: Addressing motor symptoms cognitive decline and neurodegeneration Longevity & Healthspan Rare Diseases Target: Extending healthy aging through Target: MPS-1 and MELAS redu
Slide 6: JOTROL is Neuroprotective
JOTROLTM is Neuroprotective Motor Dysfunction in MPTP Model of PD CONCLUSION: JOTROLTM DEMONSTRATES BENEFICIAL NEUROLOGIC EFFECTS IN PD 6
Slide 7: Phase 2a Clinical Advisory Board
Phase 2a Clinical Advisory Board Phase 2a, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Resveratrol (JOTROLTM) in Parkinson’s Disease (RESET) Charbel Moussa, MBBS, PhD- Zina Biopharmaceuticals, Consultant Fernando Pagan,
Slide 8: Titration and Dosing
Titration and Dosing Week 1 (QD Week 2 Week 3 Week 4 Week 5-12 capsules) (QD capsules) (QD capsules) (QD capsules) (QD capsules) Arm A 4x placebo 4x placebo 4x placebo 4x placebo 4x placebo (placebo) Arm B-200mg 3x placebo 2x placebo 2x placebo 2x placebo 2x placebo 1x100mg 2x100mg 2x100mg 2x100mg 2
Slide 9: Phase IIA JOTROL PD Study: Trial Design and Objectives
Phase IIA JOTROL™ PD Study ➢Trial Design • 30 PD patients • Randomized into placebo/MAD design • Oral administration of study drug • Once daily administration over the course of 12 weeks ➢ Study Objectives • Primary Objectives – Safety and Pharmacokinetics • Secondary Objectives – Biomarker and Targ
Slide 10: PD Trial Timelines
PD Trial Timelines – red indicates current status ▪ IND by the FDA–granted November ‘25 ▪ FPS (First Patient Screened)–expected April ‘26 ▪ FPFD (First Patient First Dose)–expected May ‘26 ▪ LPLV (Last Patient Last Visit) anticipated – expected Late ’26 ▪ Top-Line results – expected Late 26’ 10
Slide 11: Nugevia - DTC Consumer Supplements
Nugevia™ - DTC Consumer Supplements • Nugevia™ positions JUNS in the Global longevity market, with premium formulations designed for compliance and high margins • JOTROL™ resveratrol is a key ingredient in all products . High-profile brand ambassadors and scientists enhancing credibility and reach.
Slide 12: Nugevia Markets
Nugevia™ Markets • Longevity & Aging market: Explosive $T growth market including a fast-growing nutritional market’ • Existing Resveratrol market: $300M + in existing sales. • Alzheimer’s and Parkinson’s market: Customers with early onset of disease or has prevalence within their family have alread
Slide 13: Dual Approach Summary
Dual Approach Summary • Biotech: • Successful PD Trial completion in late 2026 might trigger strategic partnership discussions and start of MCI Phase II trial. • Longevity & Aging: • Digital marketing started (META, Google etc.) • Compounding pharmacy market as complementary distribution. • High-end
Slide 14: Thank You
Thank You NASDAQ: JUNS Contacts: c.rosen@Jupiterneurosciences.com a.rosen@jupiterneurosciences.com a.silva@jupiterneurosciences.com
Jupiter Neurosciences — Investor Presentation (April 2026) on 6ix